AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)
26.995 USD
-1.395 4.914%| Previous Close (in USD) | 28.39 |
|---|---|
| Change | -1.395 4.914% |
| 52 W H/L (in USD) | 62.210/26.800 |
| EBITDA (in USD) | -841.603M |
| PE Ratio | -- |
| Volume | 622269 |
| Diluted Eps TTM | -9.37 |
| Total Assets (in USD) | 513.212M |
|---|---|
| Total Liabilities (in USD) | 85.237M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 248.402M |
| Market Cap (in USD) | 4,373.527 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Employees: 239
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Vladimir Coric M.D. | Chairman & CEO | 1971 |
| 2. | Mr. Matthew Buten | Chief Financial Officer | 1961 |
| 3. | Mr. George C. Clark | VP & Chief Accounting Officer | 1984 |
| 4. | Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer | 1961 |
| 5. | Ms. Jennifer Porcelli | VP of Investor Relations | NA |
| 6. | Mr. Warren Volles | Gen. Counsel & Chief Legal Officer | NA |
| 7. | Mr. Clifford Bechtold M.S. | Chief Compliance Officer | NA |
| 8. | Ms. Kimberly Gentile | Sr. VP of Clinical Operations | 1966 |
| 9. | Mr. John Tilton | Chief Commercial Officer of Rare Diseases | 1968 |
| 10. | Mr. Chris Barrett | Sr. VP of Commercial Strategy, Common Disease | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.720 1.026% | 70.17 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.980 1.404% | 68.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.590 1.510% | 504.79 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+3.800 0.598% | 638.01 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -409.551M | -569.841M | -212.43M | -118.668M | -528.386M |
| Minority Interest | - | - | -1.81M | - | - |
| Net Income | -408.168M | -570.279M | -213.796M | -118.668M | -528.805M |
| Selling General Administrative | 56.896M | 130.86M | 37.414M | 16.046M | 134.449M |
| Gross Profit | -3.369M | -1.386M | 370.845M | -0.072M | - |
| Reconciled Depreciation | 6.912M | 1.386M | 1.393M | 0.072M | - |
| Ebit | -436.051M | -464.185M | -218.9M | -114.506M | -479.122M |
| Ebitda | -429.139M | -462.799M | -217.507M | -114.434M | -479.122M |
| Depreciation And Amortization | 6.912M | 1.386M | 1.393M | 0.072M | 0.172M |
| Operating Income | -436.051M | -567.932M | -218.9M | -114.506M | -479.122M |
| Other Operating Expenses | 436.051M | 567.932M | 218.9M | 114.506M | 479.122M |
| Interest Expense | - | 1.386M | 41.551M | - | 12.711M |
| Tax Provision | -1.383M | 0.438M | 1.366M | 0M | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | -1.383M | 0.438M | 1.366M | -0.134M | 0.419M |
| Total Revenue | 0M | 0M | 462.509M | 0M | - |
| Total Operating Expenses | 436.051M | 567.932M | 218.9M | 114.506M | 479.122M |
| Cost Of Revenue | 3.369M | 1.386M | 91.664M | 0.072M | - |
| Total Other Income Expense Net | 26.5M | -1.909M | 6.47M | -4.162M | -49.264M |
| Net Income From Continuing Ops | -408.168M | -570.279M | -848.396M | -118.668M | - |
| Net Income Applicable To Common Shares | - | -570.279M | -846.586M | -118.668M | - |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 513.212M | 661.783M | 142.061M | 111.499M | 344.264M |
| Intangible Assets | 18.4M | 18.4M | 18.4M | 39.087M | - |
| Other Current Assets | 47.375M | 19.331M | 2.121M | 0.01M | 11.554M |
| Total Liab | 85.237M | 123.012M | 47.37M | 34.718M | 351.688M |
| Total Stockholder Equity | 427.975M | 538.771M | 34.691M | 16.781M | -7.424M |
| Other Current Liab | 36.538M | 79.318M | 37.16M | 27.119M | 52.102M |
| Common Stock | 887.528M | 615.742M | 1676.792M | 1249.547M | 881.426M |
| Capital Stock | 887.528M | 615.742M | - | - | - |
| Retained Earnings | -499.292M | -91.124M | -2585.755M | -1739.169M | -972.373M |
| Good Will | 1.39M | 1.39M | 1.39M | 0M | - |
| Other Assets | 0M | 2.585M | 3.216M | 1.007M | - |
| Cash | 248.402M | 204.877M | 76.057M | 82.506M | 316.727M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 55.423M | 90.021M | 41.935M | 29.877M | 66.173M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -217.525M | -174.296M | 550.663M | 184.952M | -316.727M |
| Short Term Debt | 3.308M | - | 62.5M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 30.877M | 30.581M | 626.72M | 267.458M | - |
| Other Stockholder Equity | 39.804M | 13.869M | 169.656M | 98.938M | 83.523M |
| Property Plant Equipment | - | 52.144M | 14.69M | 13.56M | - |
| Total Current Assets | 442.446M | 586.968M | 94.823M | 89.756M | 328.281M |
| Long Term Investments | - | 0M | 6M | 7.176M | - |
| Short Term Investments | 133.417M | 260.464M | 192.648M | 223.185M | - |
| Net Receivables | 13.648M | 46.139M | 9.911M | 120.111M | - |
| Long Term Debt | - | - | 626.72M | - | - |
| Inventory | -0.396M | 56.157M | 6.734M | 39.563M | - |
| Accounts Payable | 15.577M | 10.703M | 4.775M | 2.758M | 14.071M |
| Accumulated Other Comprehensive Income | -0.065M | 0.284M | -0.073M | 0.314M | - |
| Non Currrent Assets Other | 2.4M | 2.585M | 3.216M | 1.007M | 7.831M |
| Non Current Assets Total | 70.766M | 74.815M | 47.238M | 21.743M | 15.983M |
| Capital Lease Obligations | 30.877M | 30.581M | - | - | - |
| Long Term Debt Total | - | - | 626.72M | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -304.79M | 28.27M | -2.697M | - | - |
| Total Cashflows From Investing Activities | -304.79M | 26.552M | -2.697M | - | - |
| Total Cash From Financing Activities | 767.597M | 138.447M | 152.242M | 434.593M | 340.462M |
| Net Income | -570.279M | -213.796M | -118.668M | -528.805M | -240.922M |
| Change In Cash | 165.547M | -6.449M | 73.588M | 53.478M | 132.781M |
| Begin Period Cash Flow | 77.057M | 83.506M | 9.918M | 264.249M | 131.468M |
| End Period Cash Flow | 242.604M | 77.057M | 83.506M | 317.727M | 264.249M |
| Total Cash From Operating Activities | -297.689M | -145.84M | -75.957M | -377.331M | -197.141M |
| Depreciation | 1.386M | 1.393M | 0.072M | - | - |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | -24.102M | -37.965M | - | - |
| Sale Purchase Of Stock | - | 345.626M | - | - | - |
| Other Cashflows From Financing Activities | 483.793M | 138.447M | 154.482M | 434.593M | 296.509M |
| Capital Expenditures | 41.074M | 0.938M | 2.697M | 2.534M | 4.165M |
| Change In Working Capital | -28.604M | 1.664M | 8.977M | 3.319M | 5.39M |
| Other Non Cash Items | 106.252M | 4.521M | 4.162M | 93.183M | 21.466M |
| Free Cash Flow | -338.763M | -146.778M | -78.654M | -379.865M | -201.306M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 4 months ago | 2517001 |
| 2. | iShares Russell 2000 ETF | 4 months ago | 2105813 |
| 3. | BB Biotech AG Ord | 6 months ago | 2040853 |
| 4. | Vanguard Small Cap Index | 4 months ago | 2002615 |
| 5. | T. Rowe Price Health Sciences | 4 months ago | 1986706 |
| 6. | Fidelity Select Biotechnology | 4 months ago | 1785312 |
| 7. | SPDR® S&P Biotech ETF | 4 months ago | 1480302 |
| 8. | Vanguard Small Cap Value Index Inv | 4 months ago | 1352876 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 4 months ago | 1239060 |
| 10. | Janus Henderson Global Life Sciences D | 6 months ago | 1182775 |
| 11. | Janus Henderson Global Life Sciences | 6 months ago | 1182775 |
| 12. | HBM Healthcare Investments AG Ord | 6 months ago | 893379 |
| 13. | Janus Henderson Glb Life Scn I2 USD | 4 months ago | 891424 |
| 14. | Janus Global Life Science AUSD | 6 months ago | 881508 |
| 15. | Janus Henderson Triton D | 6 months ago | 802680 |
| 16. | Janus Henderson US SMID Cap Growth | 6 months ago | 802680 |
| 17. | Fidelity Small Cap Index | 6 months ago | 763718 |
| 18. | T. Rowe Price Integrated US SmCapGrEq | 6 months ago | 738720 |
| 19. | T. Rowe Price Integrated US Sm Gr Eq | 4 months ago | 738720 |
| 20. | iShares Russell 2000 Growth ETF | 4 months ago | 679030 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 6 months ago | 7785909 |
| 2. | Stifel Financial Corp | 6 months ago | 6509261 |
| 3. | HHG PLC | 6 months ago | 6226393 |
| 4. | BlackRock Inc | 9 months ago | 6169787 |
| 5. | Suvretta Capital Management, LLC | 6 months ago | 5199219 |
| 6. | Farallon Capital Management, L.L.C. | 6 months ago | 3642589 |
| 7. | T. Rowe Price Associates, Inc. | 6 months ago | 3438526 |
| 8. | State Street Corp | 6 months ago | 3256636 |
| 9. | RP Management, LLC | 6 months ago | 2936507 |
| 10. | Bellevue Group AG | 6 months ago | 2040853 |
| 11. | FMR Inc | 6 months ago | 1841095 |
| 12. | Citadel Advisors Llc | 6 months ago | 1755121 |
| 13. | Geode Capital Management, LLC | 6 months ago | 1714612 |
| 14. | Point72 Asset Management, L.P. | 6 months ago | 1500284 |
| 15. | Perceptive Advisors LLC | 6 months ago | 1485232 |
| 16. | Adage Capital Partners Gp LLC | 6 months ago | 1482485 |
| 17. | Armistice Capital, LLC | 6 months ago | 1199495 |
| 18. | Redmile Group, LLC | 6 months ago | 1034219 |
| 19. | Schmeidler A R & CO Inc | 6 months ago | 1030239 |
| 20. | Brown Advisory Holdings Inc | 6 months ago | 968359 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...